

Common transcriptional signatures of neuropathic pain

Alexandra Pokhilko¹, Anthony Nash¹, M. Zameel Cader^{1,*}

¹ Translational Molecular Neuroscience Group, Weatherall Institute of Molecular Medicine, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom

* Corresponding Author: Translational Molecular Neuroscience Group, Weatherall Institute of Molecular Medicine, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX3 9DS, United Kingdom. telephone: 01865 231858, e-mail: zameel.cader@ndcn.ox.ac.uk

This is an open-access article distributed under the terms of the [Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 \(CCBY-NC-ND\)](#), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Abstract

The dorsal root ganglia is a key structure in nociception and chronic pain disorders. Several gene expression studies of dorsal root ganglia in pre-clinical pain models have been performed, but it is unclear if consistent gene changes are identifiable. We, therefore, compared several recent RNA-Seq datasets on the whole dorsal root ganglia in rodent models of nerve injury. Contrary to previous findings, we show hundreds of common differentially expressed genes and high positive correlation between studies, despite model and species differences. We also find, in contrast to prior studies, that 60% of the common rodent gene response after injury is likely to occur in nociceptors of the dorsal root ganglia. Substantial expression changes are observed at a one-week time-point, with

smaller changes in the same genes at a later three to four-week time-point. However, a subset of genes shows a similar magnitude of changes at both early and late time-points, suggesting their potential involvement in the maintenance of chronic pain. These genes are centred around suppression of endogenous opioid signalling. Reversal of this suppression could allow endogenous and exogenous opioids to exert their analgesic functions and may be an important strategy for treating chronic pain disorders. Currently used drugs, such as amitriptyline and duloxetine, do not appear to appropriately modulate many of the critical pain genes and indeed may transcriptionally suppress endogenous opioid signalling further

Keywords: neuropathic pain; RNAseq; animal models of pain; nerve injury pain; bioinformatics

1. Introduction

The mechanisms of neuropathic pain are complex and may vary considerably depending on the nature of the original nerve injury. These mechanisms have been investigated through different preclinical pain models (*e.g.*, injury or immune pain) and in different species (*e.g.*, mouse and rat) [3; 17; 36]. Multiple groups of genes, including neuropeptides, ion channels and genes involved in neuro-immunity, stress and regeneration are expressed in the peripheral nervous system (dorsal root ganglia (DRG)) and central nervous system (spinal cord and brain) and have been implicated in neuropathic pain. However effective therapies for neuropathic pain remain elusive, perhaps due to differences in pain mechanisms between human and animals. Additionally, tissue heterogeneity increases the complexity of interpreting neuropathic pain gene signatures. Thus, only 10-15% of DRG cells are sensory neurons, with the rest being glia and other cell types [27; 39], such that pain-specific expression change in nociceptors may be masked. Furthermore, pain-related genes, including ion channels, may be expressed at low levels, requiring sensitive methods for their detection, such as deep RNA-Seq [31].

Changes in expression of DRG genes related to neuropathic pain have been extensively studied in rodent models using microarrays and subject to meta-analysis, providing early data on the transcriptional response to nerve injury [17]. However, microarray analysis has limited coverage in comparison to RNA-Seq and to explore further the transcriptional signatures of neuropathic pain we compared several recently published RNA-Seq datasets. We used rodent data on nerve injuries that were shown to have robust and reproducible chronic pain behaviours [15]. We chose the datasets where raw data was available and the sequencing had high coverage, aiming to assess whether a common gene response in neuropathic pain was evident. We found a highly consistent differential expression of DRG genes after nerve injury and explored functional classification of the common genes and their network. Also, we used the previously developed pain interactome approach to explore the protein-protein interaction (**PPI**) networks of pain-related genes [16]. We then focused on a subset of genes with similar magnitude of differential expression at early (one-week) and later (three to four-weeks) time-points after the nerve injury. This revealed a highly connected network centred around opioid signalling. Furthermore, we observed a substantial overlap between rodent pain network genes and human genes involved in chronic pain, suggesting potential usefulness of the large collection of rodent signatures in exploratory analysis and clinical applications to human neuropathic pain. Finally, we were able to use the rodent signatures to identify potential repurposing candidate drugs for the treatment of neuropathic pain.

2. Materials and methods

2.1. Analysis of differential gene expression

We analysed four rodent DRG RNA-Seq datasets on nerve injury: two mouse dataset - **C** (from Cobos at.al., 2018, [9]) and **B** (from Baskozos at. al., 2019, [5]) and two rat datasets - **P** (from Perkins et. al. 2014,) and **Br** (from Baskozos at. al., 2019, [5]). In these datasets two injury models were used: spared nerve injury (**SNI**) for mouse datasets and spinal nerve transection (**SNT**) for rat datasets. The data were analysed from raw SRA data (for C, P datasets) or from reported counts (for

B, Br datasets). The raw RNA-Seq data consisted of paired-end 69 bp reads for C and single-end 34 bp reads for P. After trimming adapters with cutadapt (M. Martin, <https://doi.org/10.14806/ej.17.1.200>) C and P samples had mean sequencing quality (Phred) scores per base between 31.4 and 40.3. The reads were mapped to the reference genomes (mm10 for mouse; rn5 for rat) using STAR aligner [10]. 79% and 86% of reads in all samples were uniquely mapped for C and P. The mapped reads were counted to genes using the FeatureCounts function of the Subread package [19]. Differential expression was analysed using DESeq2 package in R [23]. Only genes with common names were retained for the further comparison between the datasets. In all cases the false discovery rate (FDR) adjusted *P* values for multiple-hypothesis testing with the Benjamini–Hochberg method were ≤ 0.05 and absolute value of log2 fold changes, **log2fc** ≥ 0.5 . C and P datasets had three samples per each condition (injured and control animals; C - one animal per sample; P - four pooled animals per sample). Cobos samples had four runs each (17 millions reads) and these technical replicates were collapsed into the total sums of counts after the mapping; the samples from other rodent DRG datasets (P, B, Br) had deep coverage (~50 millions reads). B dataset (bulb mouse strain) had six samples for control and four for injured animals (each sample - one animal); Br dataset had four samples (three pooled animal each) for both conditions. All datasets were based on male animals, except B, having both male and female mouse. Two outlier samples (one injured and one control) were removed from the analysis of the Br dataset based on the principle component analysis (PCA) plot of the Br samples. The retained samples (3 injured and 3 controls in both rat datasets) showed clear separation between injured and control groups (Fig. S1 A, available at <http://links.lww.com/PAIN/A972>). After the outlier removal, all rat samples were analysed together using Deseq2 (similarly, mouse samples were analysed together, Fig. S1 B, available at <http://links.lww.com/PAIN/A972>).

The technical variations between rat or mouse datasets/batches were minimized by Deseq2 package, using the design formula \sim batch + condition. This correction of technical variations was visualized (Fig. S1, S2, available at <http://links.lww.com/PAIN/A972>) by using the removeBatchEffect

function from the limma package [35] on variance stabilizing transformed counts (using `vst` function). The expression values correlated between batches for both control and injured samples, which was improved after the correction of technical variations (Fig. S2 C,D). The correction had little effect on the correlation between control and injured conditions. Unsurprisingly, given the greater number of DEGs in the rat chronic pain model, the correlation in gene expression between control versus injured samples is slightly lower for rat than for mouse datasets (DEGs are red dots on Fig. S2 C, D, available at <http://links.lww.com/PAIN/A972>). The genes, which are differentially expressed upon injury had high correlation between $\log_2\text{fc}$ for both rat and mouse datasets (red dots on Fig. S2 E, F, available at <http://links.lww.com/PAIN/A972>). However, genes not identified as differentially expressed showed a greater dispersion (black dots), which was especially pronounced in mouse datasets due to the lower proportion of DEGs in the whole transcriptome and the prevalence of non-DEGs with highly variable fold changes between datasets (Fig. S2 E,F). To demonstrate the significance of the overlaps between gene lists we performed permutation tests without replacement, using all genes with non-zero expression in at least one sample in any of the tested conditions. Thus, 19,312 expressed genes were used in the permutation test for mouse datasets and 13,940 genes for rat datasets. The differences in numbers of expressed genes between the datasets might be related to library composition and differences between species/models. The P value of the overlap was calculated using a hypergeometric distribution.

Nociceptor-related genes were identified in the whole DRG datasets using reported results of single cell RNA-Seq analysis of DEGs in DRG sensory neurons during SNT injury in mice ([14], $\log_2\text{fc} \leq 1$). The comparison of $\log_2\text{fc}$ in expression of nociceptor-related DEGs between single cell and bulk datasets demonstrated nearly - proportional changes between datasets, supporting nociceptor origin of the expression of these genes (Fig. S3). To mitigate the differences in gene expression between bulk and single cell datasets, we ranked the genes by the expression changes in single cell dataset multiplied to the differences in expression changes between single cell and the whole DRG dataset (Fig. S3A). This ranking resulted in nearly-monotonous curves for the expression changes in

both datasets, allowing visual comparison. We also used the above pipeline to analyse bulk RNA-Seq data on pooled DRG neurons during SNI injury in mice [14]. The pooled neurons dataset had six samples per condition. After trimming of adapters, the mean quality scores were between 30 and 40.3, with ~85% of the reads being uniquely mapped.

2.2.Enrichment and PPI analysis

The analysis of significantly enriched GO (Gene Ontology) terms over-represented amongst DEG lists was done with the ClusterProfiler package in R [42]. The significance of the overlap between DEG sets from the top GO terms was calculated using a hypergeometric distribution. This analysis demonstrated significant differences between most of the top DEG sets. The functional annotation clustering was performed with the TopGO package in R using conservative Elim algorithm, which minimizes false positive results by removing annotated genes from ancestor GO terms [1]. The genefilter package was used to find background genes with expression similar to DEGs. The list of pain genes was constructed based on PainNetworks and PainGene databases [18; 32] and literature curation. A PPI network was drawn using R package igraph based on the list of reported 1002 PPIs involved in pain [16]. Single edges not connected to the main network were removed. The list of pain-associated human genes was constructed based on the GWAS catalogue [7] and recent review on genetic association studies [46]. The enrichment of the orthologous rat genes with pain-related PPI human networks was analysed using the OMIM-extended library of human genetic diseases from the Enrichr web server [8].

2.3. Analysis of differential genes against cellular responses to perturbation using Connectivity

Map

The gene expression signatures of amitriptyline and duloxetine across the cell lines available on CMAP (kidney, liver, epithelial, and others), for different doses and exposure times, were exported as gct files from the Touchstone database using the clue.io online service [37]. In-house R scripts were then used to import the saved gct files and remove all Z-scores that were not statistically significant (an absolute Z-score approximately greater than 1.65). The 37 rat persistent genes were extracted from cell lines treated with 10 μ M of each drug of interest. Each gene was scored with either 1 for an anti-correlated gene expression direction, -1 for a correlated gene expression direction, or 0 if the gene was missing from that combination of dose and cell line or the Z-score was not significant. The magnitude of gene expression was not taken into account. The correlation results were filtered further for an exposure-to-drug time of six hours.

3. Results

3.1. Highly correlated gene signatures in four different rodent RNA-Seq DRG datasets of nerve injury models

We first examined two recent RNA-Seq datasets on DRG tissues derived from mouse spared nerve injury (SNI) model of neuropathic pain. In these datasets DRGs were collected at **day seven** (Cobos (C) dataset, [9]) and **day 28** (Baskozos (B) dataset, [5]) after the onset of the injury. The variations related to the technical differences between B and C datasets were corrected during the differential expression analysis using the Deseq2 package in R. To visualize the effect of technical variation, we used the removeBatchEffect function from the limma package [35]. Plotting the gene loadings before the correction showed clear separation between top PC1 and PC2 genes (Fig. S1 C, Table S1, available at <http://links.lww.com/PAIN/A972>). The genes with highest PC1 loadings are mainly related to technical variations (Fig. S1 A, available at <http://links.lww.com/PAIN/A972>) and 497

out of 500 top PC1 genes were not present amongst the top 500 PC1 genes after the correction (Fig. S1 D, left, available at <http://links.lww.com/PAIN/A972>). Noticeably, the top PC2 genes related to the effect of injury before the correction become the top 500 PC1 genes after the correction (Fig. S1 D, right; Fig S1 A, available at <http://links.lww.com/PAIN/A972>). The PCA plot showed clear separation between control and injured groups of samples (Fig. 1A; Fig. S1A, available at <http://links.lww.com/PAIN/A972>). Differential expression analysis was performed with DESeq2, using FDR adjusted $P \leq 0.05$ and $\log_2\text{fc} \geq 0.5$, identifying 966 differentially expressed genes (DEGs) for C and 474 for B. The Venn diagram of Fig. 1B demonstrates a substantial overlap between the datasets, with 233 common genes (Table S2), significantly larger than expected by chance (Fig. S2 A). We found, that changes in differential expression ($\log_2\text{fc}$ of the mean) of the common DEGs were highly positively correlated between the datasets (Fig. 1C, $R \sim 0.9$, $P < 2.2 \cdot 10^{-16}$). Similarly, there was a high correlation ($R \sim 0.89$, $P < 2.2 \cdot 10^{-16}$) between $\log_2\text{fc}$ calculated using the spread of $\log_2\text{fc}$ between replicates (Fig. S2G). The correlation of $\log_2\text{fc}$ between the genes identified as DEGs in at least one dataset were lower ($R \sim 0.6$, Fig. S2 I), therefore we used only overlapping DEGs for downstream analysis. The correlation across all genes was even lower ($R \sim 0.4$, Fig. S2 E), with many genes having high fold changes in early (C), but not in a late (B) dataset. We next examined RNA-Seq data from two independent spinal nerve transection (SNT) nerve injuries in rats. In these datasets DRG tissues were collected on day seven (Perkins (**P**) dataset, [31]) and day 21 (Baskozos rat (**Br**) dataset, [5]) post injury. For differential expression analysis we used the same criteria as for the mouse datasets (adjusted $P \leq 0.05$; $\log_2\text{fc} \geq 0.5$). After the removal of technical variations (Fig. S1 B,C,E; Table S1, available at <http://links.lww.com/PAIN/A972>), PCA plots again showed a clear separation between control and injured group of samples (Fig. 1D, Fig. S1 B). The total numbers of DEGs were 2950 for Br and 5154 for P; with 2421 common genes between the datasets (Fig. 1E; Table S3, available at <http://links.lww.com/PAIN/A972>). The size of the overlap between the rat datasets was significantly larger than would be expected by chance (Fig. S2 B). There was again a very high positive correlation ($R \sim 0.9$) between expression changes of the

common rat DEGs (Fig. 1F, Fig. S2 H,J, available at <http://links.lww.com/PAIN/A972>). The correlation between expression changes of the whole transcriptome was lower (Fig. S2 E, F, available at <http://links.lww.com/PAIN/A972>), due to the effect of non-differentially expressed genes. The ~10 times higher number of DEGs in rat compared to mouse datasets led to higher proportion of DEGs in the whole genome, and hence, higher correlation for all genes in rat compared to mouse (Fig. S2 E,F). The higher number of DEGs in rat datasets was possibly related to differences in the technical variations between labs, the injury models or less likely species differences.

The comparison of mouse and rat DEGs showed that 89 out of 233 common mouse genes were also differentially expressed in both rat datasets (Table S4), with 655 genes being present in at least one mouse and one rat datasets (Table S5). The expression changes of the common 655 mouse/rat genes were linearly correlated ($R \sim 0.7$, $P < 2.2 \cdot 10^{-16}$; Fig. 1G). Interestingly, the changes in gene expression were more drastic in rat compared to mouse, possibly due to more severe SNT trauma. Between rat and mouse models 68 of the 655 genes (10%) had opposite changes in gene expression (Fig. 1G, Table S5). The STRING analysis of these negatively correlated genes identified several connections between them, involving Calb1, Gabrg1 and Slc1a1 and, interestingly, hormonal regulatory genes (Crh, Mc4r, Tshr) (Fig. S4).

3.2. Nerve injury DRG differentially expressed genes are enriched for ion channels and neuronal membrane function

To further characterize the functional properties of the common rodent DEGs (655 genes from Table S5), we performed an enrichment analysis of ontology terms. The analysis of the functional clusters using ClusterProfiler showed over-representation of neuron- and membrane-related GO terms in the top GO category of the Cell Component (CC) (Fig. 2A, Fig. S5 E). The inflammatory response, response to wounding, blood circulation, sensory and membrane processes were amongst

the highly represented GO terms in the category of the Biological Processes (BP) (Fig. 2B, Fig. S5 F). Also, functional annotation clustering using the TopGO package with the more conservative Elim algorithm [1] showed that the top GO categories include the integral component of membrane, extracellular space, neuron cell body and plasma membrane (Fig. 2C, Table S7). The common mouse (Fig. S5 A,B,G,H) or common rat (Fig. S5 C,D,I,J) DEGs were also enriched in neuronal- and membrane-related GO terms in the CC category and processes related to membrane transport, immunity, cell motility and secretion in the BP category. We concluded that rodent DRG signatures are enriched in neuron- and membrane-related genes, in agreement with previous observations [9; 40].

3.3. Mouse DRG genes, which are differentially expressed after nerve injury are largely expressed in nociceptors

The DRG is a complex tissue constituted by several cell types including sensory neurons, fibroblasts, immune cells, satellite glial cells and Schwann cells, with neurons only representing ~10-15% of DRG cells [27; 39]. This poses a question about the relative contribution of nociceptor cells in the whole DRG transcriptome. The transcriptional responses of sensory neurons to SNT injury (day 3) were recently characterised in mice using single cell RNA-Seq [14] on individually-isolated DRG neurons, where neurons of different sizes were manually isolated and further classified based on the expression of the known markers. In this study 2386 DEGs were reported (with $\log_2fc \geq 1$) for 3 main subtypes of DRG sensory neurons: small nonpeptidergic nociceptors (**NP**); medium peptidergic nociceptors (**PEP**); and large myelinated sensory neurons, (**LM**). We used this data to estimate the numbers of genes related to nociceptive and sensory neurons amongst the common DEGs we identified above. We found that 59% of the common 233 mice DEGs from Table S2 were nociceptor (NP or PEP) - related. NP genes represented the largest group (118 genes), followed by PEP (55 genes), with many genes belonging to several types of neurons (Fig. 3A). Only a small number of differentially expressed genes (29) belong to LM sensory neurons

(Fig. 3A), consistent with predominant role of NP and PEP nociceptors in neuropathic pain [14; 38]. Furthermore, the expression changes of nociceptor-related genes in the whole DRG datasets correlated with the reported expression changes in individually-isolated nociceptor neurons (Fig. 3B, [14]), supporting a significant contribution of nociceptors to the whole DRG transcriptomic response to injury. The STRING network analysis of the genes differentially expressed in each type of sensory neurons showed an interconnected network of genes implicated in nerve injury and regeneration (*e.g.*, Atf3, Sox11, Jun, Npy, Gal) (Fig 3C; Table S1, available at <http://links.lww.com/PAIN/A972>). The interactions in PEP- and LM-related genes involved less genes (Fig. 3D,E), but were centred around the subsets of the same genes (Gal, Atf3, Nts, Csf1). For the 2421 common rat DEGs, the proportion of genes that were nociceptor-related (by mouse classification) seems to be substantially smaller, at 25%. However, neuron-related GO terms were enriched amongst the remaining 74% of the rat DEGs that were not present in the single cell analysis of mouse neuronal DEGs after nerve injury (Fig. S6, Table S8). Unsurprisingly, 62% of the core 89 DEGs (common for all four rodent datasets) were related to nociceptors (Table S4). Hence overall, our analysis demonstrates that nociceptors or neurons significantly contribute to the transcriptomic response to injury, even though neurons represent only 10-15% of DRG cells [27; 39].

3.4. Most of the differentially expressed DRG genes show consistent changes at early and late time points after nerve injury

On the PCA plots, the separation between pain and control conditions was more pronounced for early time points (day seven) compared to the later time points (day 21 or 28; Fig. 1A,D). Examining the magnitude of expression changes between early and late time points, we found that in most cases the absolute fold change of the gene expression was higher at early time points (Fig. 1C,F), in agreement with the PCA plots. Interestingly, a subset of DEGs showed a similar

magnitude of expression changes at the early and later time points ($|\log_2\text{fc}|$ at later time point $\geq |\log_2\text{fc}|$ at early time point). We found that these ‘persistent’ gene sets were different for the mouse and rat datasets - 40 out of 233 common mouse genes and 949 out of 2421 common rat genes, which might be attributed to the more severe SNT nerve injury. In most cases, genes were down-regulated (22 for mouse and 662 for rat). 50% of the mouse and 22% of the rat persistent genes were classified as neuronal by the mouse classification [14]. The enrichment analysis of the remaining 78% of rat persistent genes showed that the top DEGs ($|\log_2\text{fc}| \geq 1$) are enriched in neuron-related GO terms (Fig. 4), while the DEGs with more modest expression changes ($0.5 \leq |\log_2\text{fc}| < 1$) are enriched in mitochondrial terms (Fig. S7, Table S8). Only six genes showed persistent expression in all four rodent datasets: two upregulated genes - *Lipn* (a lipase) and *Ms4a7* (potentially involved in signal transduction) and four downregulated genes - *Slca5a1* (an organic anion transporter), *Frmpd4* (a positive regulator of dendritic spine morphogenesis), *Vsnl1* (a neuronal calcium sensor) and *Glb1l2* (a galactosidase). Overall, however, it seems that the mouse SNI and rat SNT persistent gene changes are divergent.

3.5. Downregulation of the endogenous opioid system is a central feature in the rat pain model.

To explore the pain-related protein-protein interaction (PPI) network, we used the previously published pain interactome - a PPI network of 611 inter-connected pain-related proteins [16]. Examining all common rat DEGs revealed an interconnected network of 257 genes (Fig. S8), including several hub genes related to immunity (*Il6*, *Il1a*, *Cx3cr1*) that were mainly up-regulated at day seven, but lower at day 21, which may be consistent with a time-dependent decrease of inflammation. Several regenerative hub genes of this network also show an initial increase followed by a decrease with time. This includes galanin (*Gal*), *Sprr1a*, *Adcyap1*; transcription factors *Jun*, *Fos* and *Sox11* and *Avp* (vasopressin growth factors) (Tables S1, S2, available at <http://links.lww.com/PAIN/A972>). Temporally upregulated DEGs also include *Pdyn* - a precursor of κ -opioids, having anti-nociceptive functions in inflammatory, but not in neuropathic pain [24].

Likewise, transcription factor Atf3 is up-regulated only at the early, but not late time point (Table S4). In a contrast, we found that persistently down-regulated genes include Oprm1 (μ -opioid receptor) and Penk (proenkephalin, encoding δ -opioids), both having anti-nociceptive effects in neuropathic pain [24; 46]), as well as up-regulated Cck (cholecystokinin, encoding the opioid-antagonizing peptide). Importantly, Oprm1, Penk and Cck were the key hub genes (Fig. S8) in this network.

We next investigated the 949 persistent rat genes and found that this core network consists of 148 genes, including 37 persistent DEGs (13 up- and 24 down-regulated) (Fig. 5), linking to a further 111 interaction partners (19 of the partners were non-persistent DEGs, Table S9). The key hub genes of this network were again Oprm1, Penk and Cck. In addition to the global downregulation of the opioid system, the persistent network included several other pro-nociceptive changes, such as down-regulation of anti-nociceptive glutamate receptor subunit Grin3a [26] and potassium channel regulators Kcnip3 and Kcnj3 [12; 25]. However, many changes in the persistent genes from the pain network involved anti-nociceptive mechanisms, such as up-regulation of anti-nociceptive adrenergic and dopamine receptors Adra2a and Drd2 [11; 21] and down-regulation of pro-nociceptive sodium channels Scn9a, Scn10a, Scn11a, Scn8a [4], glutamate receptors Gria2 and Grm7 [13; 29], aquaporin Aqp1 [6], ephrin receptor Ephb1 [20], tachykinin Tac1 [45] and vascular growth factor Vegfa [22]. Therefore, both anti- and pro-nociceptive changes were involved in the rat pain network based on the persistent/chronic genes.

3.6. Rat genes with persistent changes are involved in human neuropathic pain

To explore the potential relevance of rat genes to human pain, we analysed several different sources of information about human pain genes. Firstly, we found that 16 orthologues of the rat persistent genes and their neighbours on the pain network are associated with human pain in the GWAS catalogue (Table 1, top; [7]). These include nine persistent DEGs and seven neighbour genes on the pain network (3 DEGs and 4 non-DEGs). Secondly, we found that 20 rat orthologues (seven

persistent, three non-persistent and 10 neighbours) are involved in the human PPI pain network, based on the OMIM-extended library in EnrichR (Table 1, middle; [8]). Thirdly, five orthologous genes (four persistent and one non-persistent) were found to be associated with monogenic disorders with mutations implicated in human neuropathic pain (Table 1, bottom; [46]). And finally, two rat genes DRD2 and KCNJ3 were present amongst the six pain-associated genes, which were recently re-confirmed using the UKBiobank cohort [46]. In total, 42 orthologous rat genes (20 persistent) are implicated in human neuropathic pain.

3.7. Drugs used in human neuropathic pain modulate rodent chronic pain genes

We next explored the effect upon our identified persistent pain genes to drugs currently used for treatment of neuropathic pain in humans, such as amitriptyline and duloxetine. Since nociceptor specific transcriptomic drugs responses are not available, for this analysis we used the gene expression reference dataset Touchstone and the online clui.io toolset to examine drug effect in nine available non-neuronal cell lines. The 37 rat persistent genes were isolated from these Touchstone expression signatures and partitioned by whether the drug response was correlated or anti-correlated (Fig. S9-S12, available at <http://links.lww.com/PAIN/A972>) to the rat persistent gene expression (Fig. 6). Both amitriptyline and duloxetine demonstrated consistent correlated expression to many of the down-regulated rat genes including those genes, that may have an anti-nociceptive effect when down-regulated (Scn10a, Scn11a, Scn9a, Tac1, Vegfa, Gria2, Grm7, Aqp1, Ephb1). These drugs on the other hand were anti-correlated to the up-regulated rat persistent genes. The direction of the drug effects on the expression of the persistent genes was similar for most of the cell lines (Fig. 6), suggesting consistent responses, that may also occur in nociceptors.

We next attempted to identify other drugs that had an anti-correlated signature to the rat pain gene expression changes. We first removed the 12 genes that we considered as having pain ameliorating effects (marked by * on Fig. 6) as we wanted to identify drugs that ideally did not modify these

genes. Several drugs were identified including a number that increased endogenous opioid signalling, such as daunorubicin, doxorubicin and others (Fig. S13, available at <http://links.lww.com/PAIN/A972>). However, all those drugs that increased opioid signalling genes also increased pro-nociceptive genes, particularly sodium channels. Future experiments on drug effects on nociceptor cell lines would allow verification of our computational predictions and screen for drugs upregulating opioid related genes, but not pro-nociceptive genes

4. Discussion

Neuropathic pain is a highly disabling disorder, for which therapies are inadequate, and puts a considerable economic burden on society and the health service. Drug discovery efforts are costly and high risk owing to a lack of clear understanding of the mechanisms of the development and maintenance of pain [4]. Transcriptomic studies have become a common approach to understand diseases and drug mechanisms, but direct applications of transcriptomics to study human pain are hindered by the inaccessibility of relevant cells and tissues (*e.g.*, DRGs). Preclinical animal models, therefore, have become an important tool for studying neuropathic pain, but the reproducibility of findings and the relevance to human mechanism has been called into question.

Previous comparison of transcriptional changes in neuropathic pain models has been performed based on microarray studies utilising different pain models (*e.g.*, nerve injury and inflammatory) [3; 17]. A meta-analysis [17] suggested only a narrow set of common DEGs, dominated by the immune genes [3; 17]. Furthermore, there was a minimal correlation between gene expression in different models and species (rat/mouse) [17]. Although inflammation may represent an essential component of neuropathic pain, many other studies indicate an important role for changes in neuronal function after nerve injury [34; 40]. Moreover, genome-wide association and related genetic studies implicate genes involved in neurotransmission, metabolism and other non-immune functions in human neuropathic pain [46]. In agreement with these studies, we found that transcriptome changes involve a major neuronal component underlying neuropathic pain following nerve injury.

As far as we are aware, we present the first study that compares multiple RNA-Seq datasets on DRG gene expression after nerve injury. Contrary to the analysis of microarray data, we find a substantial similarity in transcriptional signatures of injury pain in rodents, suggesting common mechanisms. Thus, 233 genes were common between two mice models of the SNI injury and 2421 genes were common between two rat models of the SNT injury. The larger overlap in rat datasets was related to larger number of DEGs and large fold changes, which is likely related to species differences and also differences between models, because SNT injury is more severe compared to SNI. To verify the cell type origin of the identified DEGs, we used previously published data on gene expression in individual DRG neurons after nerve injury [14]. We should note that this classification is based upon relative enrichment of particular genes and as such is dependent on the analytical method and the fold-change cut-off. Nevertheless, the Hu et. al., 2016 assignments do appear to be consistent with other published studies.

Genes identified as differentially expressed may well be shared between neurons and other cell types. However, post-injury changes in the expression of neuronal genes show strong correlation between whole DRG and individually isolated nociceptor neurons (Fig. 3B), with a relatively stable ratio of expression changes between these datasets (Fig. S3), supporting a largely nociceptor origin of the gene expression changes in neuropathic pain. The ~ 5-fold reduction of the magnitude of expression changes in the whole DRG relative to single neurons is probably related to the “diluting” effect of other cell types. Overall, our results demonstrate that the majority of overlapping DEGs across datasets seem to be driven by neuronal responses, despite neurons representing less than 15% of DRG cells [27; 39]. This suggests that targeting of DRG peripheral neurons is a relevant strategy for developing protective therapies after nerve injury and for neuropathic pain treatments [33].

We find that early changes at one-week after injury are pronounced and affect genes involved in neuronal function, nerve regeneration and immunity, presumably as a protective transcriptional response to injury, in agreement with previous observation [9; 14]. Interestingly, however, we found that expression changes in most of these genes have much lesser magnitude after three to four

weeks of injury. It seems likely that many of these transiently altered genes are not involved in chronic pain, but are the appropriate response to nerve injury. Since each of the studies we examined had only one time-point, it is possible that the differences between the early and later time-points are simply technical differences between studies. However, it is notable that the greater magnitude of gene changes at the early time-points were evident in both mouse and rat studies and it is biologically plausible that nerve injury induces dramatic gene expression changes early, which then declines after the initial response.

Genes that show persistent changes at later weeks after injury may be more relevant to chronic pain mechanisms. Further studies with multiple time points after nerve injury are now required to explore this further. Noticeably, the immune genes, *Il1* receptor antagonist (*Il1rn*) and *Il16*, blocking cell cycle progression in resting T-cells are present amongst the upregulated persistent genes as well as *Nfkbia* and *Rela*, suggesting that at least these immune genes may have relevance to later stages after injury. These genes might be involved in neuro-immune interactions, which are known to be important in neuropathic pain [4]. Interestingly, we find many of these persisting genes, *e.g.* sodium channels *Snc9a*, *Scn10a*, *Scn11a* and glutamate receptors *Gria2* and *Grm7* have previously been implicated in pro-nociceptive pain mechanism. Down-regulation of these genes suggest an anti-nociceptive, protective transcriptional response. This highlights a challenge when interpreting this data, since in some cases it may be difficult to distinguish protective from deleterious changes. Anti-nociceptive genes of opioid signalling (μ - and δ -opioid receptors *Oprm1* and *Oprd1*; and *Penk*, coding δ -opioids) are persistently down-regulated, whilst *Cck*, encoding opioid-antagonising peptides is persistently upregulated. The down-regulation of the opioid analgesic system agrees with multiple observations on lack of efficacy of exogenous opioids in the treatment of human neuropathic pain [2]. Our analysis of the rat pain network suggests that suppression of opioid signalling is central in the network, with *Oprm1* being a top hub gene (Fig. 5). The mechanism of down-regulation of *Oprm1* expression has been shown to be dependent on methylation of its promoter by *Dnmt3a* methyltransferase, which in turn is dependent on decreased

expression of miRNA-134 [41; 44]. Consistently, we find Dnmt3a expression is upregulated after nerve injury in the two rat datasets ($\log_2\text{fc} = 0.74/0.63$ for Br/P; [41]). Additionally, histone methylation by Suv39h1 methyltransferase was shown to be involved in Oprm1 silencing [43] and again we find increased expression in two rat datasets ($\log_2\text{fc} = 0.54/0.9$ for Br/P). Therefore, several epigenetic mechanisms likely participate in the down-regulation of Oprm1 in nerve injury models. The degree of network connections of opioid signalling system might be partially exaggerated due to the opioid system being well-studied. However, the down-regulation of opioid signalling in neuropathic pain is biologically plausible [46] and aligns with the clinical experience that opioids are not effective in neuropathic pain.

We identified a number of genes from the rat SNT pain network that are implicated in human pain and genetic studies. Several of these genes have strategic locations on the rat pain network, representing hub (SCN10A, OPRD1, FOS, IL6, TNF, IL1A, NGF, DLG2) or bottleneck (SCN11, OPRD1, DRD2) genes (Fig. 5, Fig. S8). Notably, a recent analysis of DRG samples from operated cancer patients with neuropathic pain [28] identified down-regulation of κ -opioid receptor Oprk1. Therefore, drugs upregulating expression of opioid-related genes and their upstream regulators might represent strong candidates for the treatment of neuropathic pain.

Finally, we explored transcriptional drug signatures of two commonly prescribed therapeutics for neuropathic pain, duloxetine and amitriptyline. Both drugs were shown to drive changes in pain-related genes, but mostly they downregulate pro-nociceptive genes (*e.g.*, Scn11a) that are already driven in the appropriate direction to reduce pain responses after nerve injury in the rodent models. Interestingly, these drugs are able to revert the persistently upregulated neuropathic pain genes identified in our preceding analysis, including the immune-related genes, in most of the cell lines evaluated. However, they do not appear to upregulate opioid signalling. Further studies are now required to assess whether these drugs have similar effects on DRG cells. Collectively the analysis suggests at a transcriptional level these drugs do not seem ideal to counter the peripheral nerve gene

expression changes and this may explain why they have limited benefit in neuropathic pain disorders.

Our attempt to identify other drugs that might reverse the rat persistent pain signature proved to be challenging. Although we found that drugs, such as daunorubicin and doxorubicin, increased endogenous opioid genes, they did so at the cost of increasing sodium channels, which may, therefore, attenuate any pain-relieving effects. This suggests that sodium channel and opioid receptors may be co-regulated. Indeed, multiple epigenetic mechanisms (*e.g.*, histone acetylation) have been found to be involved in silencing of opioid receptors (*e.g.*, Oprm1) and sodium channels (*e.g.*, Scn10a) in neuropathic pain [30]. Further efforts are required to investigate potential therapeutic approaches that can upregulate the endogenous opioid pathway in the DRG without increasing pro-nociceptive molecules such as voltage gated sodium channel expression. We conclude that information derived from animal preclinical models of neuropathic pain can provide useful insights and relevance to human pain disorders and suggest therapeutic strategies to help alleviate this disabling disorder.

Conflicts of Interest. MZC has received honoraria from Novartis, TEVA, Orion and Eli Lilly.

Acknowledgements. We thank Prof. Caleb Webber for valuable comments on the manuscript.

Funding. The study has been funded by Oxford BRC and Oxford Cannabinoid Technologies Ltd.

Author Contributions. AP performed analysis of transcriptional signatures, AN performed drug analysis. All authors contributed to the writing of the manuscript. AP and MZC conceived and designed the study. MZC supervised the study.

Figures and Table legends

Figure 1. Comparison on the common DEGs in rodent DRG datasets on the injury pain. A.

PCA plot of variance-stabilized transformed counts for mouse: Cobos (C)-day 7 and Baskozos (B)-day 28. **D.** PCA plot of variance-stabilized transformed counts for rat: Perkins (P)-day 7 and Baskozos (Br)-day 21. To illustrate the correction of technical variations between the datasets, which was done internally by Deseq2, the PCAs were generated after applying the `removeBatchEffect` function from the `limma` package. **B,E.** Venn diagrams of DEG numbers in mouse (B) and rat (E) datasets, showing the numbers of overlapping genes. **C,F.** Linear correlation between $\log_2\text{fc}$ in expression levels relative to control non-injured DRG for the common genes (adjusted $P \leq 0.05$) in mouse (C) and rat (F) datasets. **G.** Linear correlation of the expression changes in common genes between at least one mouse and rat dataset ($|\log_2\text{fc}| \geq 0.5$; adjusted $P \leq 0.05$). The sets of the common genes were split into correlated and anti-correlated groups as indicated in the legend.

Figure 2. The GO enrichment analysis of the common rat/mouse DEGs in nerve injury models (Table S5). A,B.

The ClusterProfiler analysis of significantly enriched GO terms within the cell component (A) and biological processes (B) categories; FDR adjusted $P \leq 0.05$. **C.** TopGO analysis of the common genes with Elim method. The top categories with FDR adjusted $P < 0.01$ are shown in bright colours.

Figure 3. Sensory neurons genes are differentially expressed in mouse DRG during nerve injury.

The set of 233 common mouse DEGs from Table S2 was analysed for nociception-related genes using reported lists of mouse DEGs in DRG sensory neurons [14]. **A.** Venn diagram of the DEG numbers related to NP, PEP and LM sensory neurons, shown in blue, magenta and green respectively. **B.** Linear correlation of the whole DRG expression changes in the nociception genes with those in individual sensory neurons (NP, PEP, LM) during nerve injury [14]. **C-E.** PPI analysis of biological interactions within common mouse DEGs related to NP (C), PEP (D) or LM (E) neurons. The analysis was done with STRING, using high confidence of interactions (score 0.7) and

not more than five interactors in the first shell. The line colour indicates the type of interaction evidence. The nodes were clustered using the MCL algorithm. Those genes that did not have a direct partner in the network are not shown.

Figure 4. Enrichment analysis of the persistent rat DEGs with pronounced expression changes, which are not present in mouse dataset of sensory neurons. ClusterProfiler analysis of significantly enriched GO terms amongst DEGs with $|\log_2\text{fc}|$ at 28 days (dataset Br) \geq than at seven days (dataset P). Only highly differentially expressed genes ($|\log_2\text{fc}| \geq 1$; 304 genes total) were used. GO terms are shown within the CC (A) and BP (B) categories; FDR adjusted $P < 0.05$.

Figure 5. The pain-related PPI network of the persistent rat DEGs. The network was built based on the pain interactome [16], using rat DEGs with persistent expression changes, together with neighbours from the pain interactome network (DEGs and non-DEGs). The coloured arrows mark the type and direction of interactions; coloured nodes mark the expression changes in rat datasets (up/down/persistent/non-persistent/non-DEG partner), as explained in the legend.

Figure 6. Cell-line responses to 10 μM amitriptyline and duloxetine for 6 hours relative to the differential gene expression of rat. For each rat gene, the number of anti-correlated and correlated cell line responses from the drugs amitriptyline (A) and duloxetine (B) were collated. Genes in the rodent model whose changes are expected to have anti-nociceptive effects are indicated with an asterisk.

Table 1. Persistent rat genes and their neighbours on the pain network implicated in chronic pain conditions in human. The Table shows genes with persistent changes in time and their neighbours on the pain network of Fig. 5, which are involved in chronic pain in human. The rat gene names are shown together with orthologous human names. The persistent genes are shown by black bold, non-persistent neighbour genes - by black non-bold and non-DEG neighbours - by grey letters. The top part of the Table shows genes associated with pain in the GWAS catalogue. The next part of the Table shows enrichment of the rat genes with pain-associated human PPI networks, based on OMIM-extended library of EnrichR. The next parts of the Table show rat genes present amongst monogenic-disease genes and in genetic association studies, confirmed with the UK biobank data [46].

References

- [1] Alexa A, Rahnenfuhrer J, Lengauer T. Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. *Bioinformatics* 2006;22(13):1600-1607.
- [2] Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. *Pain* 1988;33(1):11-23.
- [3] Bangash MA, Alles SRA, Santana-Varela S, Millet Q, Sikandar S, de Clauser L, Ter Heegde F, Habib AM, Pereira V, Sexton JE, Emery EC, Li S, Luiz AP, Erdos J, Gossage SJ, Zhao J, Cox JJ, Wood JN. Distinct transcriptional responses of mouse sensory neurons in models of human chronic pain conditions. *Wellcome open research* 2018;3:78.
- [4] Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. *Cell* 2009;139(2):267-284.

- [5] Baskozos G, Dawes JM, Austin JS, Antunes-Martins A, McDermott L, Clark AJ, Trendafilova T, Lees JG, McMahon SB, Mogil JS, Orengo C, Bennett DL. Comprehensive analysis of long noncoding RNA expression in dorsal root ganglion reveals cell-type specificity and dysregulation after nerve injury. *Pain* 2019;160(2):463-485.
- [6] Borsani E. Aquaporins in sensory and pain transmission. *Current neuropharmacology* 2010;8(2):122-127.
- [7] Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, McMahon A, Morales J, Mountjoy E, Sollis E, Suveges D, Vrousitou O, Whetzel PL, Amode R, Guillen JA, Riat HS, Trevanion SJ, Hall P, Junkins H, Flicek P, Burdett T, Hindorff LA, Cunningham F, Parkinson H. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. *Nucleic acids research* 2019;47(D1):D1005-D1012.
- [8] Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, Clark NR, Ma'ayan A. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. *BMC bioinformatics* 2013;14:128.
- [9] Cobos EJ, Nickerson CA, Gao F, Chandran V, Bravo-Caparros I, Gonzalez-Cano R, Riva P, Andrews NA, Latremoliere A, Seehus CR, Perazzoli G, Nieto FR, Joller N, Painter MW, Ma CHE, Omura T, Chesler EJ, Geschwind DH, Coppola G, Rangachari M, Woolf CJ, Costigan M. Mechanistic Differences in Neuropathic Pain Modalities Revealed by Correlating Behavior with Global Expression Profiling. *Cell reports* 2018;22(5):1301-1312.
- [10] Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 2013;29(1):15-21.
- [11] Donello JE, Guan Y, Tian M, Cheevers CV, Alcantara M, Cabrera S, Raja SN, Gil DW. A peripheral adrenoceptor-mediated sympathetic mechanism can transform stress-induced analgesia into hyperalgesia. *Anesthesiology* 2011;114(6):1403-1416.

- [12] Guo YP, Zhi YR, Liu TT, Wang Y, Zhang Y. Global Gene Knockout of Kcnip3 Enhances Pain Sensitivity and Exacerbates Negative Emotions in Rats. *Frontiers in molecular neuroscience* 2019;12:5.
- [13] Hartmann B, Ahmadi S, Heppenstall PA, Lewin GR, Schott C, Borchardt T, Seeburg PH, Zeilhofer HU, Sprengel R, Kuner R. The AMPA receptor subunits GluR-A and GluR-B reciprocally modulate spinal synaptic plasticity and inflammatory pain. *Neuron* 2004;44(4):637-650.
- [14] Hu G, Huang K, Hu Y, Du G, Xue Z, Zhu X, Fan G. Single-cell RNA-seq reveals distinct injury responses in different types of DRG sensory neurons. *Scientific reports* 2016;6:31851.
- [15] Jaggi AS, Jain V, Singh N. Animal models of neuropathic pain. *Fundamental & clinical pharmacology* 2011;25(1):1-28.
- [16] Jamieson DG, Moss A, Kennedy M, Jones S, Nenadic G, Robertson DL, Sidders B. The pain interactome: connecting pain-specific protein interactions. *Pain* 2014;155(11):2243-2252.
- [17] LaCroix-Fralish ML, Austin JS, Zheng FY, Levitin DJ, Mogil JS. Patterns of pain: meta-analysis of microarray studies of pain. *Pain* 2011;152(8):1888-1898.
- [18] Lacroix-Fralish ML, Ledoux JB, Mogil JS. The Pain Genes Database: An interactive web browser of pain-related transgenic knockout studies. *Pain* 2007;131(1-2):3 e1-4.
- [19] Liao Y, Smyth GK, Shi W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. *Nucleic acids research* 2013;41(10):e108.
- [20] Liu S, Liu WT, Liu YP, Dong HL, Henkemeyer M, Xiong LZ, Song XJ. Blocking EphB1 receptor forward signaling in spinal cord relieves bone cancer pain and rescues analgesic effect of morphine treatment in rodents. *Cancer research* 2011;71(13):4392-4402.

- [21] Liu S, Tang Y, Shu H, Tatum D, Bai Q, Crawford J, Xing Y, Lobo MK, Bellinger L, Kramer P, Tao F. Dopamine receptor D2, but not D1, mediates descending dopaminergic pathway-produced analgesic effect in a trigeminal neuropathic pain mouse model. *Pain* 2019;160(2):334-344.
- [22] Llorian-Salvador M, Gonzalez-Rodriguez S. Painful Understanding of VEGF. *Frontiers in pharmacology* 2018;9:1267.
- [23] Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome biology* 2014;15(12):550.
- [24] Maldonado R, Banos JE, Cabanero D. Usefulness of knockout mice to clarify the role of the opioid system in chronic pain. *British journal of pharmacology* 2018;175(14):2791-2808.
- [25] Marker CL, Stoffel M, Wickman K. Spinal G-protein-gated K⁺ channels formed by GIRK1 and GIRK2 subunits modulate thermal nociception and contribute to morphine analgesia. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 2004;24(11):2806-2812.
- [26] Mohamad O, Song M, Wei L, Yu SP. Regulatory roles of the NMDA receptor GluN3A subunit in locomotion, pain perception and cognitive functions in adult mice. *The Journal of physiology* 2013;591(1):149-168.
- [27] Ng KY, Wong YH, Wise H. The role of glial cells in influencing neurite extension by dorsal root ganglion cells. *Neuron glia biology* 2010;6(1):19-29.
- [28] North RY, Li Y, Ray P, Rhines LD, Tatsui CE, Rao G, Johansson CA, Zhang H, Kim YH, Zhang B, Dussor G, Kim TH, Price TJ, Dougherty PM. Electrophysiological and transcriptomic correlates of neuropathic pain in human dorsal root ganglion neurons. *Brain : a journal of neurology* 2019;142(5):1215-1226.

- [29] Palazzo E, Romano R, Luongo L, Boccella S, De Gregorio D, Giordano ME, Rossi F, Marabese I, Scafuro MA, de Novellis V, Maione S. MMPIP, an mGluR7-selective negative allosteric modulator, alleviates pain and normalizes affective and cognitive behavior in neuropathic mice. *Pain* 2015;156(6):1060-1073.
- [30] Penas C, Navarro X. Epigenetic Modifications Associated to Neuroinflammation and Neuropathic Pain After Neural Trauma. *Frontiers in cellular neuroscience* 2018;12:158.
- [31] Perkins JR, Antunes-Martins A, Calvo M, Grist J, Rust W, Schmid R, Hildebrandt T, Kohl M, Orengo C, McMahon SB, Bennett DL. A comparison of RNA-seq and exon arrays for whole genome transcription profiling of the L5 spinal nerve transection model of neuropathic pain in the rat. *Molecular pain* 2014;10:7.
- [32] Perkins JR, Lees J, Antunes-Martins A, Diboun I, McMahon SB, Bennett DL, Orengo C. PainNetworks: a web-based resource for the visualisation of pain-related genes in the context of their network associations. *Pain* 2013;154(12):2586 e2581-2512.
- [33] Pettingill P, Weir GA, Wei T, Wu Y, Flower G, Lalic T, Handel A, Duggal G, Chintawar S, Cheung J, Arunasalam K, Couper E, Haupt LM, Griffiths LR, Bassett A, Cowley SA, Cader MZ. A causal role for TRESK loss of function in migraine mechanisms. *Brain : a journal of neurology* 2019;142(12):3852-3867.
- [34] Reinhold AK, Batti L, Bilbao D, Buness A, Rittner HL, Heppenstall PA. Differential transcriptional profiling of damaged and intact adjacent dorsal root ganglia neurons in neuropathic pain. *PloS one* 2015;10(4):e0123342.
- [35] Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic acids research* 2015;43(7):e47.

- [36] Rodriguez Parkitna J, Korostynski M, Kaminska-Chowaniec D, Obara I, Mika J, Przewlocka B, Przewlocki R. Comparison of gene expression profiles in neuropathic and inflammatory pain. *Journal of physiology and pharmacology : an official journal of the Polish Physiological Society* 2006;57(3):401-414.
- [37] Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, Gould J, Davis JF, Tubelli AA, Asiedu JK, Lahr DL, Hirschman JE, Liu Z, Donahue M, Julian B, Khan M, Wadden D, Smith IC, Lam D, Liberzon A, Toder C, Bagul M, Orzechowski M, Enache OM, Piccioni F, Johnson SA, Lyons NJ, Berger AH, Shamji AF, Brooks AN, Vrcic A, Flynn C, Rosains J, Takeda DY, Hu R, Davison D, Lamb J, Ardlie K, Hogstrom L, Greenside P, Gray NS, Clemons PA, Silver S, Wu X, Zhao WN, Read-Button W, Wu X, Haggarty SJ, Ronco LV, Boehm JS, Schreiber SL, Doench JG, Bittker JA, Root DE, Wong B, Golub TR. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. *Cell* 2017;171(6):1437-1452 e1417.
- [38] Tandrup T, Woolf CJ, Coggeshall RE. Delayed loss of small dorsal root ganglion cells after transection of the rat sciatic nerve. *The Journal of comparative neurology* 2000;422(2):172-180.
- [39] Thakur M, Crow M, Richards N, Davey GI, Levine E, Kelleher JH, Agley CC, Denk F, Harridge SD, McMahon SB. Defining the nociceptor transcriptome. *Frontiers in molecular neuroscience* 2014;7:87.
- [40] Xiao HS, Huang QH, Zhang FX, Bao L, Lu YJ, Guo C, Yang L, Huang WJ, Fu G, Xu SH, Cheng XP, Yan Q, Zhu ZD, Zhang X, Chen Z, Han ZG, Zhang X. Identification of gene expression profile of dorsal root ganglion in the rat peripheral axotomy model of neuropathic pain. *Proceedings of the National Academy of Sciences of the United States of America* 2002;99(12):8360-8365.

- [41] Xu B, Cao J, Zhang J, Jia S, Wu S, Mo K, Wei G, Liang L, Miao X, Bekker A, Tao YX. Role of MicroRNA-143 in Nerve Injury-Induced Upregulation of Dnmt3a Expression in Primary Sensory Neurons. *Frontiers in molecular neuroscience* 2017;10:350.
- [42] Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. *Omics : a journal of integrative biology* 2012;16(5):284-287.
- [43] Zhang J, Liang L, Miao X, Wu S, Cao J, Tao B, Mao Q, Mo K, Xiong M, Lutz BM, Bekker A, Tao YX. Contribution of the Suppressor of Variegation 3-9 Homolog 1 in Dorsal Root Ganglia and Spinal Cord Dorsal Horn to Nerve Injury-induced Nociceptive Hypersensitivity. *Anesthesiology* 2016;125(4):765-778.
- [44] Zhou XL, Yu LN, Wang Y, Tang LH, Peng YN, Cao JL, Yan M. Increased methylation of the MOR gene proximal promoter in primary sensory neurons plays a crucial role in the decreased analgesic effect of opioids in neuropathic pain. *Molecular pain* 2014;10:51.
- [45] Zimmer A, Zimmer AM, Baffi J, Usdin T, Reynolds K, Konig M, Palkovits M, Mezey E. Hypoalgesia in mice with a targeted deletion of the tachykinin 1 gene. *Proceedings of the National Academy of Sciences of the United States of America* 1998;95(5):2630-2635.
- [46] Zorina-Lichtenwalter K, Parisien M, Diatchenko L. Genetic studies of human neuropathic pain conditions: a review. *Pain* 2018;159(3):583-594.

Table 1. Persistent rat genes and their neighbours on the pain network implicated in chronic pain conditions in human. The Table shows genes with persistent changes in time and their neighbours on the pain network of Fig. 5, which are involved in chronic pain in human. The rat gene names are shown together with orthologues human names. The persistent genes are shown by black bold, non-persistent neighbour genes - by black non-bold and non-DEG neighbours - by grey letters. Top part of the Table shows genes associated with pain in the GWAS catalogue. The next part of the Table shows enrichment of the rat genes with pain-associated human PPI networks, based on OMIM-extended library of EnrichR. The next parts of the Table show rat genes present amongst monogenic-disease genes and in genetic association studies, confirmed with the UK biobank data [45].

Based on GWAS catalogue							
human gene	rat gene	description	chronic pain condition	pval	log2fc Br	log2fc P	PubMed ID
CBLN4	Cbln4	cerebellin 4 precursor	Migraine without aura	$8 \cdot 10^{-6}$	-5.81	-2.71	23793025
GDAP1	Gdap1	ganglioside-induced differentiation-associated-protein 1	Dysmenorrheic pain	$7 \cdot 10^{-7}$	-1.39	-1.38	27454463
GPD2	Gpd2	glycerol-3-phosphate dehydrogenase 2	NP* in joint replacement surgery for osteoarthritis	$3 \cdot 10^{-6}$	-0.54	-0.52	28051079
HJURP	Hjurp	Holliday junction recognition protein	Migraine	$3 \cdot 10^{-9}$	1.23	1.11	27322543
IL1RN	Il1rn	interleukin 1 receptor antagonist	Dysmenorrheic pain	$7 \cdot 10^{-7}$	2.37	1.82	27454463
MPPE D2	Mpped 2	metallophosphoesterase domain containing 2	Migraine	$4 \cdot 10^{-8}$	-1.58	-1.49	27322543
RB1CC 1	Rb1cc1	RB1-inducible coiled-coil 1	Dysmenorrheic pain	$4 \cdot 10^{-6}$	-0.65	-0.62	29855537
SCN11 A	Scn11a	sodium voltage-gated channel alpha subunit 11	Migraine	$8 \cdot 10^{-6}$	-4.41	-2.77	23793025
ZMYN	Zmynd	zinc finger, MYND-	Migraine	$4 \cdot 10^{-8}$	0.76	0.75	27182965

D8	8	type containing 8					
DLG2	Dlg2	discs large MAGUK scaffold protein 2	Migraine without aura	$1 \cdot 10^{-12}$	-0.56	-0.86	28952330
IL1A	Il1a	interleukin 1 alpha	Dysmenorrheic pain	$2 \cdot 10^{-16}$	1.85	8.63	29855537
IL1R1	Il1r1	interleukin 1 receptor type 1	P pain in head and neck squamous cell carcinoma	$3 \cdot 10^{-6}$	1.16	1.91	27670397
GRIN2A	Grin2a	glutamate ionotropic receptor NMDA type subunit 2A	Dysmenorrheic pain	$1 \cdot 10^{-7}$	-	-	29855537
IL1B	Il1b	interleukin 1 beta	Dysmenorrheic pain	$2 \cdot 10^{-16}$	-	-	29855537
PRKCA	Prkca	protein kinase C alpha	NP in joint replacement surgery for osteoarthritis	$4 \cdot 10^{-6}$	-	-	28051079
REST	Rest	RE1 silencing transcription factor	Migraine	$3 \cdot 10^{-9}$	-	-	27322543

Based on OMIM extended library of EnrichR

pain condition	overlap	p adj	genes
rheumatoid arthritis	18/90	$6.9 \cdot 10^{-11}$	IL10;OPRD1;HSP90AA1;FUS;STAT3;CSNK2A2;PTPRK;FOS;IK3R1;NFKB1;EGFR;RELA;RUNX1;IL6;CREB1;PRKACA;DRD2;JAK2
migraine	17/93	$9.73 \cdot 10^{-5}$	OPRD1;HSP90AA1;FUS;STAT3;CSNK2A2;PTPRK;FOS;PIK3R1;TNF;NFKB1;EGFR;RELA;CREB1;PRKACA;DRD2;JAK2 ;SCN1A

Genes causing monogenic NP (based on Zorina 18)

rodent gene	human gene	description	chronic pain conditions	log2fc Br	log2fc P	PubMed ID
GLA	Gla	galactosidase, alpha	Small fibre neuropathy	-1.07	-0.92	26866599
SCN10A	Scn10a	sodium voltage-gated channel alpha subunit 10	Idiopathic painful small fibre neuropathies	-3.28	-2.35	26711856, 23115331, 23986244
SCN11A	Scn11a	sodium voltage-gated channel alpha subunit 11	Idiopathic painful small fibre neuropathies	-4.41	-2.77	25791876, 24776970, 28298626, 24036948,


						26746779
SCN9A	Scn9a	sodium voltage-gated channel alpha subunit 9	Peripheral neuropathy, Radicular pain, DNP, Erythromelalgia	-1.46	-1.26	14985375, 18945915, 17145499, 15958509, 17167479, 20635406, 21094958
IL6	Il6	interleukin 6	Radicular pain	2.38	5.72	18321738, 15733644, 29240606

NP-associated genes supported by BioBank data (based on Zorina 18)


rodent gene	human gene	description	chronic pain conditions	log2fc Br	log2fc P	PubMed ID
DRD2	Drd2	dopamine receptor D2	Neuropathic pain	1.33	0.65	25180011, 29240606
KCNJ3	Kcnj3	potassium voltage-gated channel subfamily J member 3	Cancer pain	-1.61	-1.61	24392765, 29240606

*NP-neuropathic pain


A mouse




D rat




B




E




C



F




G




rat/mouse common


A



B




C




mouse nociceptors

A




B




C

NP genes




D

PEP genes




E

LM genes





rat persistent not in mouse nociceptor DEGs

A




B





Amitriptyline



Duloxetine

